Scholarlink

<p>The ESMO Congress 2025 highlighted major advances in breast cancer, with numerous clinically relevant abstracts, some of which were immediately practice-changing. In hormone receptor-positive/HER2-negative breast cancer, adjuvant abemaciclib has now demonstrated an overall survival benefit in the monarchE study, while the 5‑year update from the NATALEE trial showed a&#xa0;sustained benefit with adjuvant ribociclib. These findings suggest a&#xa0;durable carryover effect of CDK4/6 inhibition beyond the treatment period in the adjuvant treatment of hormone receptor-positive/HER2-negative breast cancer. In HER2-positive breast cancer, trastuzumab deruxtecan is emerging as a&#xa0;treatment option in both adjuvant and neoadjuvant settings, based on data from the DESTINY-Breast05 and DESTINY-Breast11 trials. In metastatic triple-negative breast cancer, both sacituzumab govitecan and datopotamab deruxtecan have demonstrated superiority over conventional chemotherapy, and antibody–drug conjugates are now considered the standard of care in the first-line setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

ESMO 2025: Highlights in breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月2日

查看全文
  • Amelie Sandner,
  • Simon Udovica,
  • Muna Ferner,
  • Maximilian Marhold,
  • Kathrin Strasser-Weippl,
  • Rupert Bartsch

摘要

The ESMO Congress 2025 highlighted major advances in breast cancer, with numerous clinically relevant abstracts, some of which were immediately practice-changing. In hormone receptor-positive/HER2-negative breast cancer, adjuvant abemaciclib has now demonstrated an overall survival benefit in the monarchE study, while the 5‑year update from the NATALEE trial showed a sustained benefit with adjuvant ribociclib. These findings suggest a durable carryover effect of CDK4/6 inhibition beyond the treatment period in the adjuvant treatment of hormone receptor-positive/HER2-negative breast cancer. In HER2-positive breast cancer, trastuzumab deruxtecan is emerging as a treatment option in both adjuvant and neoadjuvant settings, based on data from the DESTINY-Breast05 and DESTINY-Breast11 trials. In metastatic triple-negative breast cancer, both sacituzumab govitecan and datopotamab deruxtecan have demonstrated superiority over conventional chemotherapy, and antibody–drug conjugates are now considered the standard of care in the first-line setting.